4//SEC Filing
Venker Eric 4
Accession 0001140361-25-038126
CIK 0001635088other
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 9:00 PM ET
Size
13.4 KB
Accession
0001140361-25-038126
Insider Transaction Report
Form 4
Venker Eric
President & Immunovant CEO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-10-13−20,727→ 851,383 totalExercise: $15.85Exp: 2026-03-31→ Common Stock (20,727 underlying) - Exercise/Conversion
Common Shares
2025-10-09$15.85/sh+104,940$1,663,299→ 1,609,899 total - Exercise/Conversion
Common Shares
2025-10-13$15.85/sh+20,727$328,523→ 1,525,686 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-09−104,940→ 872,110 totalExercise: $15.85Exp: 2026-03-31→ Common Stock (104,940 underlying) - Sale
Common Shares
2025-10-13$16.25/sh−20,727$336,814→ 1,504,959 total - Sale
Common Shares
2025-10-09$16.30/sh−104,940$1,710,522→ 1,504,959 total
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
Documents
Issuer
Roivant Sciences Ltd.
CIK 0001635088
Entity typeother
Related Parties
1- filerCIK 0001801917
Filing Metadata
- Form type
- 4
- Filed
- Oct 13, 8:00 PM ET
- Accepted
- Oct 14, 9:00 PM ET
- Size
- 13.4 KB